GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TaiwanJ Pharmaceuticals Co Ltd (ROCO:6549) » Definitions » Capex-to-Operating-Income

TaiwanJ Pharmaceuticals Co (ROCO:6549) Capex-to-Operating-Income : 0.00 (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is TaiwanJ Pharmaceuticals Co Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

TaiwanJ Pharmaceuticals Co's Capital Expenditure for the six months ended in Dec. 2023 was NT$0.00 Mil. Its Operating Income for the six months ended in Dec. 2023 was NT$-18.90 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


TaiwanJ Pharmaceuticals Co Capex-to-Operating-Income Historical Data

The historical data trend for TaiwanJ Pharmaceuticals Co's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TaiwanJ Pharmaceuticals Co Capex-to-Operating-Income Chart

TaiwanJ Pharmaceuticals Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

TaiwanJ Pharmaceuticals Co Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 0.12 -

Competitive Comparison of TaiwanJ Pharmaceuticals Co's Capex-to-Operating-Income

For the Biotechnology subindustry, TaiwanJ Pharmaceuticals Co's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TaiwanJ Pharmaceuticals Co's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TaiwanJ Pharmaceuticals Co's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where TaiwanJ Pharmaceuticals Co's Capex-to-Operating-Income falls into.



TaiwanJ Pharmaceuticals Co Capex-to-Operating-Income Calculation

TaiwanJ Pharmaceuticals Co's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-1.441) / -6.61
=N/A

TaiwanJ Pharmaceuticals Co's Capex-to-Operating-Income for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / -18.904
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TaiwanJ Pharmaceuticals Co  (ROCO:6549) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


TaiwanJ Pharmaceuticals Co Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of TaiwanJ Pharmaceuticals Co's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


TaiwanJ Pharmaceuticals Co (ROCO:6549) Business Description

Traded in Other Exchanges
N/A
Address
Rm. D207, Number 2, Sec.2, ShengYi Road, Hsinchu Biomedical Science Park, Hsinchu County, Zhubei, TWN, 30261
TaiwanJ Pharmaceuticals Co Ltd is a Taiwan based specialty pharmaceutical company focused on small molecules for unmet medical needs like chronic organ inflammation of metabolic, autoimmune and infectious etiologies. It is also involved in developing novel chemical entities (NCEs) for chronic liver diseases and allergy/asthma.

TaiwanJ Pharmaceuticals Co (ROCO:6549) Headlines

No Headlines